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Sepsis and septic shock in newborns causes mortality and morbidity depending on the
organism and primary site. ECMO provides cardiorespiratory support to allow adequate
organ perfusion during the time for antibiotics and source control surgery (if needed) to
occur. ECMO mode and cannulation site vary depending on support required and local
preference. Earlier and more aggressive use of ECMO can improve survival.
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INTRODUCTION
Sepsis secondary to a bacterial, a viral, or a fungal infection during the first 28 days of life remains
a significant cause of mortality and long-term morbidity. Despite advances in neonatal care and
maternal antibiotic prophylaxis for group B streptococcus (GBS), the incidence of neonatal sepsis
remains high with 1–4 cases every 1,000 live births in the USA with mortality and long-term
disability affecting 40% of neonates with sepsis (1–3). Risk factors for the development of sepsis in
the neonatal period can be maternal (prolonged rupture of membranes, poor or no antenatal care,
meconium-stained liquor, premature labor and chorioamnionitis, GBS colonization) and neonatal
(prematurity, low birth weight, APGAR 5min<5, male gender, resuscitation at birth, neutropenia,
lack of enteral feeding, need for vascular catheters and mechanical ventilation) (4). While GBS and
Escherichia Coli are the most common bacteria involved, viral sepsis (Herpes Simplex Virus, HSV)
and fungal infections are responsible for increased mortality and neurological sequelae, especially
in the premature group. Mortality rates for neonatal sepsis vary between 10 and 30% across studies
based on gestational age (term vs. birth weight <1,000 g, 52% vs. 72%, respectively) and pathogen
(up to 73% for systemic candidiasis) (1, 5–7).
Neonatal sepsis is a heterogeneous entity with different clinical presentations depending on the
time of onset and is classified as early (within the first 72 h of life) and late-onset (beyond 72 h
of life). These differences correlate with the physiological changes the myocardium and vascular
system undergo during the first weeks of life.
The definition of sepsis in neonates is adapted from the pediatric population complicating
further diagnosis and management of neonatal sepsis; in a retrospective review of term neonates,
only 53% of the cases of culture-positive early-onset sepsis were diagnosed by the consensus
definition (8, 9).
Extracorporeal mechanical oxygenation (ECMO) is routinely used around the world to support
children and adults with respiratory and/or cardiovascular dysfunction with increasing numbers
of children supported over the last three decades (10). The American College of Critical Care
Medicine, in their latest edition of the neonatal sepsis guidelines, recommends ECMO for refractory
shock as last tier intervention whenmedical management has failed (11). Despite early reluctance of
the ECMO community in supporting adults and children with septic shock due to high morbidity
andmortality, ECMOhas been routinely utilized for the neonatal population with reported survival
rate of up to 70% (12–16).
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ECMO survival 50–77% (13, 16, 17) 31–74% (16, 18, 19) 22–78% (20–22)
HR, heart rate; DO2, oxygen delivery; PMN, polymorphonuclear cells; BM, bone marrow; PVR, pulmonary vascular resistance; RV, right ventricle; LV, left ventricle; CI, cardiac index;
SVR, systemic vascular resistance; PPHN, persistent pulmonary hypertension on the newborn.
NEONATAL CARDIOVASCULAR
PHYSIOLOGY VS. CHILDREN AND
ADOLESCENTS
The neonatal myocardium has functional and structural features
that differ markedly from the heart of older children and adults
(Table 1). The myocardium has less contractile protein per 100
grams of tissue than an older child’s heart; only half of the tissue
is composed of contractile elements while the remaining 50%
is made of connective tissue, large nuclei, and mitochondria
(see Figure 1). Therefore, the mass of the myocardium is
reduced, as well as its compliance and contractile capacity
and reserve. Equally important is the “disorganization” of the
neonatal myocardium as compared to the well-organized sheets
of muscle of the older child’s heart. The reduced compliance of
the heart leads to higher filling pressure and reduced pre-load
augmentation (23–25). These factors limit the reserve capacity of
the neonatal heart, making it highly dependent on heart rate and
susceptible to negative inotropic drugs or acidosis. While adults
hearts can double or triple their heart rate to maintain oxygen
delivery (high output shock), the high baseline rate of neonates
limits this compensatory mechanism. Furthermore, differently
from adult hearts, cardiac function is highly dependent on the
resting beta-adrenergic stimulation leading to a reduced response
to beta-agonist agents, meaning higher doses are required in
neonates to achieve the same effect.
The neonatal myocardium expresses less alpha-adrenergic
receptors which contribute to the reduced left ventricular
function. To compensate for the reduced myocardial function,
the concentration of circulating catecholamines is higher
than in adults; therefore, the higher depressing effect in
neonates on cardiac output by anesthetic agents. Calcium ion
transport in the myocardial cells is fundamental to guarantee
contraction and relaxation. Myocardial sarcolemma and T-
tubular system is less well-developed and calcium entry into cells
is compromised in the newborn. Also, neonatal myocytes have
reduced mitochondrial calcium and rely mostly on extracellular
calcium for contractility; volatile agents used in anesthesia,
modulate calcium inflow and can lead to severe myocardial
depression in neonates. Decreased kinetics of cytosol calcium
contribute to delay in diastolic relaxation (26, 27).
During fetal life, the circulation is in parallel with equal
right and left ventricular pressures, right ventricular (RV)
predominance, and half of the cardiac output directed to
the placenta circulation for its low vascular resistance. After
cord clamping and initiation of ventilation, systemic vascular
resistance (SVR) rises, and pulmonary vascular resistance (PVR)
falls with rising in left atrial (LA) pressure and closure of
the foramen oval (FO), and transition to a series circulation,
finalized after several days by closure of the ductus arteriosus
(through increase in oxygen tension, endothelin I and catechol
amines and reduction in prostaglandins). Early infections during
this transition period can interfere with this process leading to
PPHN, right to left shunt via FO and persistent ductus arteriosus
(PDA) (25).
During sepsis, the difference between neonates, children, and
adults have also been described at the level of endothelium
and interaction between pathogen and immune system (28).
Differently from adults, neonates have reduced recruitment
of polymorphonucleate cells (PMN) to the site of infection,
diminished phagocytic activity, and intracellular killing by
reactive oxygen radicals, and a higher pathogen load per ml
of blood as part as a “microbe-tolerant” strategy (29, 30).
Furthermore, in vitro studies showed lower levels of circulating
TNF, IL-1B, and IL10 (31).
CLINICAL FEATURES OF SEPSIS IN
NEONATES VS. CHILDREN AND
ADOLESCENTS
During the neonatal period, depending on gestation age,
the timing of infection (early vs. late-onset), etiology
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FIGURE 1 | Stained myocardial section in a neonate and a 12 year old at
same magnification.
(bacterial, fungal, or viral), and primary focus (pneumonia
vs. systemic), sepsis can present with different clinical features of
cardiovascular disturbance.
Lack of transition from fetal to neonatal circulation with
severe PPHN and persistent fetal circulation (PFC) is a frequent
complication of early-onset sepsis. Therapeutic target remains
agents that act on reduction of PVR and RV support.
Late-onset sepsis can have the same clinical features of
early onset sepsis or can present with increased SVR and
severely reduced left ventricular (LV) function and cardiac
output, disseminated intravascular coagulation (DIC), and
multiorgan failure (MOF). Older children with septic shock, or
“cold shock,” manifest the same features of severely depressed
myocardial function.
Clinical features of septic shock in adults are reduced
SVR (hypotension), standard or increased cardiac index,
tachycardia and increasedmixed venous saturations. This clinical
presentation is also described as “warm shock” or distributive
shock (32, 33). This is uncommon in children and very rare in
neonates due to the developmental differences mentioned above.
INDICATIONS FOR ECMO IN NEONATAL
SEPSIS
From 2012 to 2017, the Extracorporeal Life Support Organization
(ELSO) reports that, of all neonates receiving ECMO, in
<10% the indication was sepsis (34). In neonates where sepsis
presents as RV failure, pulmonary hypertension and hypoxemia,
indications for initiation of mechanical support do not differ
from the ones for respiratory and/or cardiovascular failure
secondary to meconium aspiration, congenital diaphragmatic
hernia or pneumonia: oxygenation index >40 for more than
4 h, failure to wean from 100% oxygen despite maximal medical
therapy, severe hypoxic respiratory failure and pulmonary
hypertension with evidence of RV and/or LV failure. On the
other hand, for neonates whose sepsis presents with systemic
inflammatory response (SIRS), refractory septic shock (RSS), and
MOF, the only indication for mechanical support provided by
the latest ESLO guidelines is “pressor resistant hypotension”
(34). At the current state, there is no consensus on level of
inotropic/vasoactive support, level of organ dysfunction, time
frame from onset to MOF or rapidity of medical therapy
escalation that should trigger ECMO initiation for neonates with
RSS. Validation of the septic shock scores for pediatric RSS in
the neonatal population could potentially identify in future more
targeted clinical parameters [vaso-inotrope score (VIS), arterial
lactate andmyocardial dysfunction] on the timing of ECMO (35).
ECMO MODALITY DURING NEONATAL
SEPSIS
Depending on the critical clinical features of sepsis, neonates have
been supported with different modalities of ECMO.
Veno-Venous ECMO
During veno-venous ECMO (VV-ECMO), blood is drained
from the venous system [superior vena cava (SVC) or inferior
vena cava (IVC)] or right atrium (RA) and returned into
the venous system (SVC or IVC) or RA after carbon dioxide
removal and oxygenation. Historically, this modality was deemed
to provide only respiratory support although by decreasing
ventilation, it can augment cardiac output by decreasing lung
over-distension thus reducing PVR and increasing venous return
to the LA, improve coronary blood oxygen content and LV
performance, and diminish intrathoracic pressure. Neonates with
severe pneumonia and sepsis, manifesting as severe PPHN, are
the best candidates for VV-ECMO support. In clinical practice,
there have been no predictors able to identify for which neonates
VV-ECMO will provide sufficient myocardial support not to
need veno-arterial support. Failing cardiovascular support with
persistent acidosis, reduced lactate clearance and low mixed
venous saturation (SvO2) on VV-ECMO should trigger early
conversion to VA-ECMO via cannulation of the carotid artery.
In an ELSO database review of ECMO in septic children, VV-
ECMO was mostly used in the neonatal age (87%) compared to
older children (13%) and associated with improved survival when
compared to VA-ECMO (83% vs. 70%, respectively) (16). Both in
adults and children supported for respiratory failure, VV-ECMO
was associated with lower complications rates and improved
survival (36, 37). In the 2019 report from the Karolinska Institute
on ECMO for septic shock in adults, VV-ECMO was associated
with reduced ECMO and hospital survival when compared to VA
(60 vs. 85%, respectively); survival was also higher for adults with
LV failure (90%) when compared to distributive shock (64.7%)
(20). This study reinforces the concept of different outcomes for
the same condition depending on clinical features and modality
of support for it.
VV-ECMO has a safer profile than VA-ECMO not requiring
arterial cannulation and subsequent potential risk of arterial
embolic phenomena to the brain, to the splanchnic region, and
to the peripheries. A major downside of veno-venous support
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remains the potential for recirculation and hypoxemia. Since
2009, double-lumen cannulae were introduced, and have been
widely utilized, to obviate for the risk of recirculation. Despite the
positive aspect of requiring single vascular access, these devices
are difficult to position correctly in neonates and children, and
allow partial support when compared to a two cannulae strategy.
In a single center review comparing complications of dual-lumen
cannula vs. a two cannulae approach, children supported with a
dual lumen-cannula had increased mechanical complications on
ECMO and seizure episodes (38).
Veno-Arterial ECMO
Peripheral VA-ECMO
Septic neonates in whom the clinical presentation is dominated
by severely depressed myocardial function with progressive left
ventricular dilatation and increased systemic vascular resistance
(SVR) require VA-ECMO. This modality provides the best level
of cardiovascular support to the failing heart, ensuring adequate
blood flow, and oxygen delivery to organs. It also allows a
decrease of inotropic drugs and vasopressors with their potential
complications. During peripheral VA-ECMO, blood is drained
via a cannula in the SVC/RA and is returned through a cannula
inserted in the carotid artery and tip positioned ideally at the
junction with the aortic arch. Cerebrovascular accidents (cerebral
infarction or hemorrhage) remain themore significant and severe
complication. In an ELSO database review, 22% of neonates
cannulated peripherally onto VA-ECMO developed a neurologic
injury (39). Despite lack of evidence, carotid artery repair, and
not ligation after decannulation could potentially limit long term
neurological complication; many centers do this.
Left atrial (LA) dilatation due to poor myocardial function
and /or myocardial stunning can delay left ventricular recovery
and cause pulmonary hemorrhage; this is particularly likely in the
settings of severe left ventricular failure pre-ECMO or differential
ventricular function with right better than left. Signs of LA
hypertension on echo, lack of native myocardial ejection, and LV
dilatation should trigger ECMO flows and SVR manipulation;
consideration should rapidly be given to LA decompression via
percutaneous atrial septostomy, percutaneous cannulation of the
LA via the Foramen Ovale or direct surgical LA cannulation.
After ECMO initiation, an echo should also document the
presence of a patent ductus arteriosus which might contribute to
high pulmonary to systemic flow ratio (Qp:Qs), arterial diastolic
steal (reverse flow in aorta during diastole) and pulmonary over
circulation with increasing levels of lactate or lack of clearance,
pulmonary oedema and hemorrhage, contributing to higher
morbidity of this modality.
Central VA-ECMO
While peripheral VA-ECMO might be sufficient to ensure
adequate cardio circulatory support for isolated cardiogenic or
cold shock, in the presence of distributive shock or mixed
shock (distributive and cardiogenic), higher ECMO flows may
be required to maintain adequate end-organ oxygen delivery
and function. Central cannulation is primarily utilized in the
post-cardiotomy pediatric population and in ECMO centers with
cardio surgical programs.
Thismodality is similar to what happens in a cardiac operating
theater during cardiopulmonary bypass (CPB); the sternum is
open, blood is drained via a large bore cannula placed directly
into the RA and returned into the ascending aorta. Higher
flows up to 200–250ml/kg/min can be achieved to meet the
circulatory needs during mixed cardiogenic/distributive shock.
Rarely low dose vasopressors (Vasopressin or Noradrenaline
infusions) might be required to achieve physiological blood
pressure for age. Flows should be adjusted to guarantee the best
oxygen delivery to tissue (SvO2 60–70%) and flow adequate to
meet metabolic demand and clear lactate (lactate <2 mmol/L);
counter to intuition, continuous infusion of systemic vasodilators
(and not ECMO flow reduction) might be required to manage
hypertension on this high flow. This is usual for the first 6 h
of mechanical support. As time passes and organ resuscitation
continues, flow reduction is possible and guided by SvO2, lactate,
peripheral perfusion and individual organ function.
Left heart distention is a possible complication as for
peripheral VA-ECMO, and direct drainage of LA or LV can
be addressed during the cannulation process as well as the
ligation of a PDA. Disadvantages remain the invasive nature of
the procedure, the potential for secondary mediastinal infection
and high risk of bleeding, especially in neonates with liver
dysfunction, DIC, and coagulopathy. During the first 24–48 h
of support aggressive blood products replacement with Platelets,
Fresh Frozen Plasma (FFP), and Cryoprecipitate might be
required. Chest exploration for mediastinal blood accumulation
and inspection for secondary bleeding points is frequently needed
and clot removal is mandatory to limit secondary fibrinolysis and
consumptive coagulopathy which can worsen bleeding. Careful
monitoring of inlet and outlet pressures are fundamental when
high ECMO flows on centrifugal pumps are utilized, in order to
avoid hemolysis or cavitation. High ECMO flows and excessively
negative venous pressure (<-20 mmHg) can lead to hemolysis
which is associated with increased odds of ICU and in hospital
mortality (40).
Duration of ECMO
The duration of ECMO support for sepsis is generally 4–6
days and varies on the microorganism, clinical presentation
(pneumonia vs. shock), timing of ECMO and pre-existing end-
organ dysfunction. In the 2012–2016 ELSO registry report,
168 neonates received ECMO for sepsis, 41 of which had
primary diagnosis of pneumonia and an average duration of
support of 163 h (longest duration of 1,155 h) (34). Similar
duration of mechanical support is reported in other single
center studies on neonates and children with sepsis (18,
41, 42). Longer duration of ECMO might be expected for
neonates with chronic or pre-ECMO lung disease and/or
acute post-infective lung damage with cystic transformation
to limit ventilator induced lung injury (VILI). The efficacy
of antimicrobial therapy, the onset of any complications on
ECMO, the development of other organ failures and the neonates’
lung function all contribute to prolongation of ECMO; if
lung disease is prominent and ECMO is needed for another
5–7 days, then conversion from VA to VV is common.
Likewise, the adequacy of ECMO support has to be reassessed
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TABLE 2 | Neonatal reports for ECMO and sepsis.







Meyer et al. (13) 1,060 neonates (S) 1,060 (S) ELSO registry
retrospective
77 77 CPR pre-ECMO, low pH & high
ventilatory rate
Reiterer et al. (14) 43 neonates resp. failure 9 (RSS) SCR 65 44 –
Skinner et al. (16) 4,551 children (S) 3,645 (S) ELSO registry
retrospective
68 73 VA-ECMO compared to
VV-ECMO
Chang et al. (19) 55 children (RSS) 4 (RSS) SCR 31 25 Higher SOFA score
Rambaud et al. (15) 22 children (RSS) 14 (RSS) ELSO registry
retrospective
59 64 Higher inotropic requirement
pre-ECMO
Sole et al. (17) 21 children (RSS) 12 (RSS) SCR 43 50 Disease time before ECMO
S, sepsis; RSS, refractory septic shock; SCR, single center retrospective.
during the run and consideration placed on conversion to a
different cannulation strategy. Conversion from VV to VA-
ECMO might be required in neonates with early PPHN/PFC
and worsening signs and symptoms of cardiogenic/distributive
shock. Persistent lung disease and respiratory failure after the
resolution of cardiovascular instability might trigger conversion
from VA to VV-ECMO. Long term VV-ECMO for 3–6 months
might be required for severe lung parenchyma injury (HSV
cystic pneumonia or necrotizing pneumonitis, severe VILI).
An alternative cannulation modality recently deployed in our
center is transthoracic RA-PA ECMO which offers reduced
mechanical complications (cannula migration, skin breakdown
and site infection), no recirculation and RV support. Destination
of therapy might involve lung transplant or withdrawal of active
treatment in the face of no lung recovery and in countries where
neonatal/infant lung transplant is not undertaken.
Furthermore, increased duration of ECMO can be expected
in the presence of secondary acquired infections (43, 44).
This risk is higher in previously septic neonates because
of the immaturity of the immune system, because of the
immunosuppression due to the initial pathogen leading to
ECMO and the immunomodulatory effect of the circuit itself. In
a 2018 report by Cashen, although not affecting outcome, 16% of
neonates and children on ECMO acquired a secondary infection
at a median time of 5.2 days from initiation (45).
RISK FACTORS AND OUTCOME
ECMO for neonatal sepsis has been utilized for over three
decades with variable survival rates (Table 2). An ELSO registry
report from 2014 to 2019 describes 119 neonates supported for
sepsis with a survival rate of 51% (12). Survival rate for older
children vary from to 43 to 74% based on local experience,
while reported mortality for adults remains high, up to 75%
(17, 18, 21, 46) (Table 1).
A multitude of factors influences the outcome after ECMO.
Even a simple binary measure like survival or death is
dependent on underlying pathogen and natural history of the
disease, on clinical presentation and timing of support, on
individual risk factors (age, weight, maturity of immune system,
nutritional status), on the modality of support and the onset
of complications.
Underlying etiological microorganism has been described as
influencing outcome.
Survival with bacterial sepsis has been reported up to 75%;
mortality for candida infection pre-ECMO remains very high in
neonates (61%), children (69%), and adults (81%) (47).
Only one in four neonates supported with ECMO for
herpes (HSV) survived, with sepsis/septic shock independently
associated with mortality (OR 10.2) (42).
Similarly, survival after adenoviral infection for neonates
supported with ECMO was only 11% (48). The high mortality
for neonates on ECMO for disseminated viral infections might
be correlated to the immaturity of the immune system, especially
in premature babies, together with the invasive nature of the
viral pathogen responsible for severe neurological and hepatic
cytotoxic effect.
In a large ELSO review of 7,190 neonates supported on
ECMO, the authors identified birth weight<3Kg, gestational age
<34 weeks andVA-ECMO as factors associated with neurological
events, especially cerebral hemorrhage. In the same review, of
366 neonates supported for sepsis, 33% developed a neurological
injury (49).
It remains difficult to ascertain if the onset of neurological
events is solely due to ECMO or intrinsic to the natural history
of the disease. In a retrospective cohort review of neonates with
bacteremia, neurological complications were present in 19.4%
of the study population who presented with septic shock and
associated with a 57.1% mortality (50).
Similarly, intraventricular hemorrhage (IVH) grade III and
IV were reported in 18% of premature babies with antenatal
infection compared to 8.6% without infection (51).
Over the last two decades, as ECMO deployment has become
standard of care for tertiary units, outcomes have improved, and
complications have diminished, eligibility criteria have become
less rigid. Gestational age lower than 34 weeks and birth weight
under 2Kg have become relative contraindications, while IVH
grade III or IV and lethal chromosomal abnormality remained
absolute contraindications. No significant difference in mortality
for neonatal sepsis on ECMO were described for gestational age
of 34 weeks (41%) and 29–33 weeks GA (46%) (52).
Timing of mechanical support for neonates with sepsis
remains difficult to establish, but one can postulate that early
reversal of tissue oxygen debt and organ dysfunction would
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improve outcome. While no data are available in neonates,
in an adult case series by Cheng, ECMO for sepsis within
96 h from admission was associated with better survival when
compared to later support (60 vs. 19%), reflecting an earlier
reversal of multiorgan dysfunction (53). Similarly, for septic
adults, persistence of shock beyond 30.5 h before ECMO
initiation was associated with no survival, accentuating
the importance of timing of reversal of cardiovascular
dysfunction (22). Higher lactate pre-cannulation, a pH <
7.2, higher VIS and the presence of a cardiac arrest pre-
ECMO have been identified as predictors for increased ECMO
mortality (19, 54).
While ECMO remains a supportive therapy, administration
of adequate antimicrobial therapy remains fundamental to
improve survival of septic neonates. Vast interest in ECMO
research, for the last decade, has been the pharmacokinetic (PK)
and the pharmacodynamics (PD) of medications, especially of
antimicrobials, during ECLS. Neonates have an immature liver
and kidney and their capacity of metabolizing and excreting
drugs varies between individuals. Septic neonates represent
even more a complex system because of fluid overload and
changes in distribution volume (Vd), multiorgan dysfunction
(kidneys and liver), hypoalbuminemia, capillary leak, and
disruption in perfusion. Adding an ECMO circuit to the equation
modifies further the Vd and allows for medications to be
sequestered within its component (both polyvinylchloride of
tubing and poly-methyl pentene of the oxygenator). Careful
dosing and monitoring of the efficacy of antimicrobial therapy is
fundamental for successful weaning off mechanical support. In a
recent review, Raffaeli gives great insight in the pharmacotherapy
of antimicrobials, sedatives and inotropic drugs for neonates
supported with ECMO (55).
FUTURE DIRECTIONS
Earlier Use of ECMO With Better
Technology and Less Sick Patients
Survival and long-term sequelae post-ECMO are multifactorial,
only some of which are modifiable when a septic neonate
is referred for ECMO. Early referral and/or transfer to an
ECMO center might reduce the time neonates are exposed
to high ventilatory pressures, and limit potential VILI, and
excessive inotropic and vasopressor support. Established end-
organ dysfunction pre-ECMOmight not allow the deployment of
“safer” ECMOmodalities (VV vs. VA-ECMO) and could increase
the complication rates on ECMO (bleeding and/or thrombosis,
renal dysfunction, fluid overload, and need for RRT, high blood
products requirements, neurological accidents). An ELSO review
by Polito identified cardiac arrest and lower pH at ECMO
initiation risk factors for neurological complications in neonates
(cerebral hemorrhage, infarction, seizures, and brain death) (49).
Several other pediatric series highlight the weight of pre-ECMO
lactate on ECMO survival (18, 56, 57). Close collaboration
with neonatologists and open discussion about local protocols
and indications/inclusion criteria for ECMO could reduce the
delay between clinical presentation and ECMO cannulation, and
therefore improve outcomes.
Role of Adjunctive Extracorporeal
Therapies
Despite limited data specific for the neonatal septic population,
utilization of adjunctive extracorporeal techniques during ECMO
has become standard practice. In a retrospective analysis of
pediatric admissions for sepsis between 2004 and 2012 collected
via Pediatric Health Information System (PHIS), 169 children
under 1 year of age received both ECMO and renal replacement
therapy (RRT) (58). Hypoxia, arterial hypotension, low cardiac
output state, diastolic steal via PDA, and high vasoactive support
can lead to acute kidney injury (AKI) in neonates with sepsis (59).
In a mixed pediatric and neonatal report, the incidence of AKI on
ECMO was of 60–74% while in a retrospective cohort study on
neonates on ECMO, the presence of AKI was associated with a 3.2
Odds Ratio of death (60, 61). Renal replacement therapy (RRT)
is commonly used in patients on ECMO to obviate for fluid
overload and AKI, both associated with increased duration of
circulatory support and mortality (60, 61). Furthermore, both in
vitro and animal studies, have shown reduction of inflammatory
mediators in sepsis and post cardio-pulmonary bypass (62, 63).
In a case series by Blijdorp, the deployment of RRT in neonates
on ECMO was associated with reduced duration of ECMO and
ventilatory support (64).
Although the deployment and timing of RRT during ECMO
remains controversial with non-neonatal studies showing either
increased mortality or unaffected outcome, physiologically
early renal support seems the best approach to reverse fluid
overload and/or maintain even fluid balance, correct electrolyte
disequilibrium, remove cytokines and enhance caloric intake
(58, 61, 65, 66).
Thrombocytopenia-associated multi-organ failure (TAMOF)
secondary to sepsis has been focus of interest over the last
5 years and has triggered utilization of plasma exchange
(PE) techniques for patients off and on ECMO. In a clinical
picture similar to thrombotic thrombocytopenic purpura (TTP),
inflammatory mediators during sepsis can inhibit or inactivate
ADAMTS-13, a metalloprotease whose deficiency leads to
microangiopathic thrombosis, end-organ dysfunction and death.
Children with TAMOF receiving PE have shown improved
28-days survival and reduction in end-organ dysfunction
(67). In a case series of 14 children on ECMO for sepsis-
related MOF and TAMOF, utilization of PE was associated
with reduced organ failure index and VIS with a survival
of 71.4% (68). Despite promising results of this technique
in this subgroup of children, routine deployment should
be balanced with the potential complications caused by it
(hypotension, hypocalcaemia, coagulopathy, removal of protein-
bound medications and antibiotics) (69).
Limited experience based on single case reports is
available for extracorporeal blood purification techniques
(EBPTs). Adsorptive therapies have been utilized mostly
for hyperinflammatory syndromes (hemophagocytic
lymphohystiocitosis, macrophage activation syndrome) or
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toxin-mediated infections manifesting as SIRS/septic shock.
Two clinical reports from Japan on non ECMO neonates with
sepsis/toxic shock highlight the potential adoption of these
techniques on ECMO (70, 71). Similarly, non ECMO studies on
adults with septic shock treated with HA330 adsorption cylinder
showed improved hemodynamic parameters and decreased
mortality (72).
Adequacy of ECMO Blood Flow
In a multicenter study of children supported with ECMO for
septic shock, VA-ECMO showed beneficial effect for children
with a cardiac arrest and ECMO flows over 150 ml/kg/min were
associated with higher survival compared to “standard” flows
(survival 82 vs. 43%) (56).
Anticoagulation Is More Complex Than in
Children/Adolescents
Anticoagulation for neonates on ECMO is difficult because of the
immaturity of their clotting pathways and their hypercoagulable
state, and propensity for cerebral hemorrhage. In a large
prospective observational cohort study, bleeding and thrombotic
events in neonates receiving respiratory ECMO were 60% and
43% respectively; furthermore, 22% of the events were cerebral
hemorrhage while 3.3% were intracranial infarctions (73).
Bleeding and thrombotic events are responsible for increased
morbidity and mortality on ECMO (73–75).
Neonates present a unique and very fine balance between
anticoagulant and procoagulant state. Neonatal platelet activity
is reduced compared to children and adults compensating
the increased level of von Willebrand factor. Plasma levels
of clotting factors are reduced while there is reduced
expression of anticoagulant factors (protein C and S and
antithrombin III) (76). Sepsis with DIC and thrombocytopenia
puts neonates at very high risk for both thrombotic and
hemorrhagic complications and adds further complexities to the
anticoagulation regimen.
Precipitant that disrupt the fine neonatal hemostatic
homeostasis like sepsis and/or ECMO lead to platelet activation
and secondary depletion, complement cascade activation,
leukocytemargination and cytokine release, thrombin generation
and subsequently secondary fibrinolysis are responsible for both
hemorrhagic and/or thrombotic events and the difficulty of
managing anticoagulation on ECMO. In a neonatal ECMO
report by Doymaz, low fibrinogen (<150 mg/dL) and low
platelet count (<50.000/µL) were associated with increased risk
for intracranial hemorrhage (77).
Inconsistency of blood test results due to the small volumes of
blood and reagents make goal setting for anticoagulation difficult
and varied throughout the world. This is particularly relevant
to APTT and ACT but less so with INR and Anti-Xa. Bedside
tests such as TEG or Rotem are increasingly being evaluated.
Exposure to the foreign surface of the ECMO circuits only
accentuates the existing coagulopathy with further consumption
of clotting factors and platelets (78, 79). Future biocompatible
materials might limit the need for systemic anticoagulation or
antiplatelet agents on ECMO limiting transfusion requirements
and hemorrhagic or thrombotic events. Circuits that act as nitric
oxide donors have been investigated for this purpose for the last
decade (80–82).
CONCLUSIONS
High survival rates can be achieved for neonates with bacterial
sepsis and septic shock and ECMO should be always considered
in the absence of severe intracerebral pathology. Worse outcome
is associated with non-bacterial sepsis, extreme prematurity, need
for ECPR, higher lactate and severity of organ dysfunction pre-
ECMO. Predominant pathophysiological features should dictate
modality of support (VV-ECMO for right ventricular failure and
PPHN, VA-ECMO for left ventricular failure and RSS). Future
study is warranted to determine the optimal timing of support.
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